MX2022010417A - Medicamentos en aerosol. - Google Patents

Medicamentos en aerosol.

Info

Publication number
MX2022010417A
MX2022010417A MX2022010417A MX2022010417A MX2022010417A MX 2022010417 A MX2022010417 A MX 2022010417A MX 2022010417 A MX2022010417 A MX 2022010417A MX 2022010417 A MX2022010417 A MX 2022010417A MX 2022010417 A MX2022010417 A MX 2022010417A
Authority
MX
Mexico
Prior art keywords
dimethyltryptamine
methoxy
aerosol
aerosols
dmt
Prior art date
Application number
MX2022010417A
Other languages
English (en)
Inventor
Theis Terwey
Original Assignee
Gh Res Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gh Res Ireland Limited filed Critical Gh Res Ireland Limited
Publication of MX2022010417A publication Critical patent/MX2022010417A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Abstract

Se proporcionan aerosoles de 5-metoxi-N,N-dimetiltriptamina (5-MeO-DMT) o una sal farmacéuticamente aceptable que son útiles para la administración a un paciente a través de una vía de inhalación. Los aerosoles tienen densidades de masa de partículas de aerosol en el intervalo de aproximadamente 0,5 mg/l a aproximadamente 12,5 mg/l.
MX2022010417A 2020-02-24 2021-02-24 Medicamentos en aerosol. MX2022010417A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20159161.7A EP3868364A1 (en) 2020-02-24 2020-02-24 Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
PCT/EP2021/054502 WO2021170614A1 (en) 2020-02-24 2021-02-24 Aerosol comprising 5-methoxy-n.n-dimethyltryptamine

Publications (1)

Publication Number Publication Date
MX2022010417A true MX2022010417A (es) 2022-09-07

Family

ID=69740131

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010417A MX2022010417A (es) 2020-02-24 2021-02-24 Medicamentos en aerosol.

Country Status (15)

Country Link
US (1) US20230075124A1 (es)
EP (2) EP3868364A1 (es)
JP (1) JP2023513954A (es)
KR (1) KR20220164704A (es)
CN (1) CN115427019A (es)
AU (1) AU2021228914A1 (es)
BR (1) BR112022015758A2 (es)
CA (1) CA3172772A1 (es)
CL (1) CL2022002303A1 (es)
CO (1) CO2022012059A2 (es)
CR (1) CR20220417A (es)
IL (1) IL295758A (es)
MX (1) MX2022010417A (es)
PE (1) PE20221577A1 (es)
WO (1) WO2021170614A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021250435A1 (en) 2020-06-12 2021-12-16 Beckley Psytech Limited Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
EP4159192A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders
EP4159201A1 (en) * 2021-09-30 2023-04-05 Biomind Labs Inc Encapsulated microparticles and nanoparticles of dimethyltriptamines
WO2023186823A1 (en) * 2022-03-27 2023-10-05 GH Research Ireland Limited Treatment of cognitive dysfunction
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19803376C1 (de) 1998-01-29 1999-10-14 Markus Storz Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten
US20070122353A1 (en) * 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
JP2005503425A (ja) * 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
WO2002094216A2 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of stimulants through an inhalation route
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
WO2004104490A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
ES2355983T3 (es) 2006-08-01 2011-04-01 STOBI GMBH & CO. KG Balón de válvula para inhaladores .
WO2019081764A1 (en) * 2017-10-26 2019-05-02 Consejo Superior De Investigaciones Científicas (Csic) ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS
EP4353314A2 (en) 2019-02-22 2024-04-17 GH Research Ireland Limited 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating major depression

Also Published As

Publication number Publication date
CO2022012059A2 (es) 2022-11-29
PE20221577A1 (es) 2022-10-06
JP2023513954A (ja) 2023-04-04
IL295758A (en) 2022-10-01
US20230075124A1 (en) 2023-03-09
CN115427019A (zh) 2022-12-02
EP4110295A1 (en) 2023-01-04
CR20220417A (es) 2022-10-10
CA3172772A1 (en) 2021-09-02
CL2022002303A1 (es) 2023-01-27
EP3868364A1 (en) 2021-08-25
KR20220164704A (ko) 2022-12-13
AU2021228914A1 (en) 2022-10-13
WO2021170614A1 (en) 2021-09-02
BR112022015758A2 (pt) 2022-10-11

Similar Documents

Publication Publication Date Title
MX2022010417A (es) Medicamentos en aerosol.
AU2014205529B2 (en) Methods and compositions for treatment of demyelinating diseases
US20050026868A1 (en) Phosphorus-containing macrocycles
Weber Molecular therapies of cancer
YU80000A (sh) Farmaceutske formulacije za aerosolove sa dve ili više aktivnih supstanci
NZ760541A (en) Aerosol pirfenidone and pyridone analog compounds and uses thereof
MXPA04004173A (es) Formas orales de liberacion controlada utiles para la reduccion o prevencion de la ansiedad hacia la nicotina.
MX342062B (es) Composicion farmaceutica para administracion oral.
PH12021550302A1 (en) Methods for the administration of certain vmat2 inhibitors
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
JP2012533554A5 (es)
TR201910393T4 (tr) Bir inhalatör için ağızlık.
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
TNSN05048A1 (en) Inhalation compositions with high drug ratios
KR20150136074A (ko) 저용량 이리노테칸염산염 수화물을 함유하는 항종양제
WO2021070200A3 (en) Stable compositions of (7as,2's)-2-oxoclopidogrel and its pharmaceutical salts
ZA202103090B (en) Pharmaceutical formulations of cyclosporine analogs
Papaseit et al. Surviving life-threatening MDMA (3, 4-methylenedioxymethamphetamine, ecstasy) toxicity caused by ritonavir (RTV)
TW200420554A (en) A intra-airway administrating preparation
NO20040500L (no) 1, 3, 5-triazin-2, 4, 6-trioner, fremstilling og anvendelse som gonadotropin-frigjorende hormon reseptor antagonister
MX2022015057A (es) Metodo para administracion pulsatil de un farmaco gaseoso.
CO2021007141A2 (es) Composiciones inhalables para usarse en el tratamiento de enfermedades pulmonares
MX2020014043A (es) Composiciones inhalables que comprenden inmunosupresores macrociclicos.
JP2015510517A5 (es)
WO2023114943A3 (en) Lipids for use in lipid nanoparticle formulations